The article you requested is
Suicidal Ideation and Varenicline: A Possible Case of Mistaken Adverse Drug Reaction?
J Clin Psychiatry 2008;69:1834-1835 [letter]
Copyright 2008 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
- Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: Varenicline, an a4ß2 nicotinic acetylcholine partial agonist,
has been licensed in the United Kingdom (and approved in
the United States) for the treatment of tobacco dependence
since 2006. Studies have shown varenicline to result in higher
smoking cessation rates over placebo, bupropion, and nicotine
replacement therapy (NRT). In the one study conducted to
date, varenicline was also seen to be effective in smokers with
mental illness, there being no evidence of excess adverse events
or exacerbation of preexisting conditions.